Welcome to our dedicated page for Enochian Biosciences news (Ticker: ENOB), a resource for investors and traders seeking the latest updates and insights on Enochian Biosciences stock.
Enochian Biosciences, Inc. (ENOB) is a clinical-stage biopharmaceutical company developing innovative immunotherapies targeting HIV/AIDS and cancer. This dedicated news hub provides investors and stakeholders with timely updates on therapeutic advancements, regulatory milestones, and corporate developments.
Access authoritative information about ENOB's research pipeline including ENO-1001 (pre-IND HIV cure candidate) and ENO-3001 (colon cancer relapse prevention). The page consolidates official announcements regarding clinical trial progress, SEC filings, partnership opportunities, and strategic business decisions.
Key updates cover three critical areas: 1) Clinical development stages across therapeutic candidates 2) Regulatory interactions and compliance updates 3) Financial performance and stockholder communications. All content is sourced from verified corporate disclosures to ensure reliability.
Bookmark this page for streamlined access to Enochian Biosciences' latest news. For complete investment context, always cross-reference updates with official SEC filings and company-issued documentation.
Enochian BioSciences has accelerated its Pre-Investigational New Drug (Pre-IND) submission to the FDA following significant results from studies on a potential cancer therapy. The therapy, which reduced tumor volumes by 77-87% in mouse models, targets solid tumors, including pancreatic cancer, with an IND application expected in early 2024. The company has raised approximately $2.5 million through a private placement and is eligible for up to $27 million in non-dilutive grants. Notable researchers, including Dr. Anahid Jewett from UCLA, are involved, indicating strong scientific backing for the upcoming clinical trials.
Enochian BioSciences (NASDAQ: ENOB) announced promising proof-of-concept data from humanized mouse studies presented by Dr. Anahid Jewett at the Innate Killer Summit. The studies showed significant reductions in pancreatic tumor weight and volume when treated with the Company’s proprietary cell-, gene-, and immunotherapy technology. Dr. Jewett highlighted the reproducibility of results across two independent studies as encouraging. The Company plans to submit a Pre-IND to the FDA soon, with potential applications for other solid tumors and chronic infectious diseases like HIV. The results present an opportunity for accelerated drug development.
Enochian BioSciences Inc. (NASDAQ: ENOB) has announced its full compliance with NASDAQ listing requirements after filing essential reports. The Annual Report on Form 10-K was submitted on February 27, 2023, followed by Quarterly Reports on Forms 10-Q for the respective quarters on March 7 and March 9, 2023. Lead Independent Board Member, Gregg Alton, expressed satisfaction with the Company’s compliance status. CEO Dr. Mark Dybul emphasized the importance of this milestone and the company's strong scientific foundation, mentioning plans to advance novel technology targeting solid tumors, potentially progressing to clinical phases by early 2024.
Enochian BioSciences (NASDAQ: ENOB) received a notice from Nasdaq regarding non-compliance with Listing Rule 5250(c)(1) due to delayed filings of Form 10-Q for the period ended December 31, 2022. This follows previous notices for not filing its Annual Report on Form 10-K and Quarterly Report for September 30, 2022, resulting in ongoing non-compliance. Although there is no immediate effect on its listing status, failure to comply by April 11, 2023, may result in delisting. The company has submitted a plan to regain compliance, which has been accepted by Nasdaq.
Enochian BioSciences received a notice from Nasdaq regarding non-compliance with Listing Rule 5250(c)(1) due to the company's failure to file its Form 10-Q for the period ended September 30, 2022. This follows a previous notice for not filing its Form 10-K for the period ended June 30, 2022. The delays are attributed to ongoing evaluation of company assets by a third-party valuator. While this notice does not immediately affect the company's stock listing, failure to regain compliance within given timelines may lead to delisting.
Enochian BioSciences (NASDAQ: ENOB) announced progress in its oncology platform, receiving a U.S. patent and achieving promising early results from studies with Dr. Ana Jewett at UCLA. The company is also awaiting results from HIV platform studies at the Fred Hutchinson Cancer Center. CEO Dr. Mark Dybul expressed optimism about advancing curative therapies for serious diseases. Additionally, Enochian filed a lawsuit against several parties for allegedly falsifying study results related to its Hepatitis B and SARS-CoV-2/influenza pipelines, claiming substantial harm.
Enochian BioSciences recently received a notice from Nasdaq indicating non-compliance with Listing Rule 5250(c)(1) due to the failure to file its Form 10-K. The company has 60 days to either file the report or submit a compliance plan. While this notice does not lead to immediate delisting, failure to comply could result in the removal of its common stock from Nasdaq. The company can appeal if Nasdaq rejects its compliance plan, which may extend the deadline up to 180 days.
